Sign in
Active, not recruitingPhase 1/2

A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

Key facts

Who runs it
Denali Therapeutics Inc.
Where
Chapel Hill, Chicago, Oakland, and Pittsburgh, United StatesSee the 4 sitesAlso in 3 other countries, 3 sites
Status
Active, not recruiting
Phase
Phase 1/2
People taking part
47 people enrolled
Started
16 Jul 2020
Expected to end
Feb 2031
Type of study
Interventional, 5 groups
Treatments tested
  • tividenofusp alfa
Record updated
7 August 2025

Who can take part

Age
Up to 18 years
Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (15)Hide the full registry criteria

Who can take part

  • Confirmed diagnosis of MPS II
  • Cohort A: Participants aged ≥5 to ≤10 years with neuronopathic MPS II
  • Cohort B: Participants aged ≥1 to ≤18 years with non-neuronopathic MPS II, neuronopathic MPS II, or unknown phenotype
  • Cohort C: Participants aged <4 years with neuronopathic MPS II (this cohort can include participants ≥4 to ≤18 years of age if participant is a blood relative of a participant <4 years of age)
  • Cohort D: Participants aged ≤18 years with non-neuronopathic MPS II or neuronopathic MPS II with preexisting hepatomegaly who have never taken standard-of-care ERT
  • Cohort E: neuronopathic MPS II participants aged ≥6 years at screening, non-neuronopathic MPS II participants <6 or ≥17 years at screening, and neuronopathic MPS II participants ≥1 to ≤18 years at screening with a history of prior haematopoietic stem cell transplantation or gene therapy who have completed at least 48 weeks in Study DNLI-E-0001
  • For participants receiving intravenous iduronate 2-sulfatase (IDS) ERT, tolerated a minimum of 4 months of therapy during the period immediately prior to screening

Who cannot take part

  • Use of any CNS-targeted MPS II ERT within 3 months before study start for participants aged ≥5 years, and within 6 months before study start for participants aged <5 years
  • Use of IDS gene therapy or stem cell therapy at any time (except for participants in Cohort E)
  • Clinically significant thrombocytopenia, other clinically significant coagulation abnormality, or significant active bleeding, or required treatment with an anticoagulant or more than two antiplatelet agents
  • Have had a ventriculoperitoneal (VP) shunt placed, or any other brain surgery, or have a clinically significant VP shunt malfunction within 30 days of screening
  • Unstable or poorly controlled medical condition(s) or significant medical or psychological comorbidity or comorbidities that, in the opinion of the investigator, would interfere with safe participation in the trial or interpretation of study assessments
  • Have a clinically significant history of stroke, status epilepticus, head trauma with loss of consciousness, or any CNS disease that is not MPS II-related within 1 year of screening
  • Have any clinically significant CNS trauma or disorder that, in the opinion of the investigator, may interfere with assessment of study endpoints or make participation in the study unsafe
  • Contraindication for lumbar punctures

Where in United States

Also in 3 other countries, 3 sites

  • UNC Children's Research InstituteChapel Hill, United States
  • Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United States
  • UCSF Benioff Children s HospitalOakland, United States
  • UPMC Children's Hospital of PittsburghPittsburgh, United States

About the trial

What the trial wants to find out

This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme replacement therapy (ERT), designed to treat both the peripheral and CNS manifestations of Mucopolysaccharidosis type II (MPS II; Hunter syndrome).

Read full original descriptionShow less

Participants, whose physicians feel they are deriving benefit, will have the opportunity to be reconsented into a safety extension and then an open-label extension for continued evaluation.

The 5 groups in the trial

  • Cohort ATreatment being tested

    Dose escalation followed by a consistent dose level in participants with neuronopathic MPS II

    Treatment: tividenofusp alfa

  • Cohort BTreatment being tested

    A consistent dose level in participants with non-neuronopathic MPS II, neuronopathic MPS II, or unknown phenotype followed by dose escalation in some participants.

    Treatment: tividenofusp alfa

  • Cohort CTreatment being tested

    A consistent dose level in participants with neuronopathic MPS II

    Treatment: tividenofusp alfa

  • Cohort DTreatment being tested

    A consistent dose level in participants with non-neuronopathic MPS II or neuronopathic MPS II

    Treatment: tividenofusp alfa

  • Cohort ETreatment being tested

    A consistent dose level in participants with non-neuronopathic MPS II or neuronopathic MPS II

    Treatment: tividenofusp alfa

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome
Publications
Record updated
7 August 2025